Endocrine/metabolic https://www.bioworld.com/rss en-us CMS to Bridge coverage for obesity drugs as BALANCE teeters http://www.bioworld.com/articles/730497 Wed, 22 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730497-cms-to-bridge-coverage-for-obesity-drugs-as-balance-teeters Generic injection pens Hinova Pharmaceuticals presents new prodrugs of orforglipron http://www.bioworld.com/articles/730567 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730567-hinova-pharmaceuticals-presents-new-prodrugs-of-orforglipron Insilico Medicine divulges new NLRP3 inflammasome inhibitors http://www.bioworld.com/articles/730550 Tue, 21 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730550-insilico-medicine-divulges-new-nlrp3-inflammasome-inhibitors Tokyo universities describe new compounds for dyslipidemia http://www.bioworld.com/articles/730526 Mon, 20 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730526-tokyo-universities-describe-new-compounds-for-dyslipidemia Obesity-focused Kailera goes for US biopharma record with $625M IPO BioWorld data.]]> http://www.bioworld.com/articles/730403 Fri, 17 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730403-obesity-focused-kailera-goes-for-us-biopharma-record-with-625m-ipo Gold IPO with chart Ascletis Pharma discovers new THR-β agonists http://www.bioworld.com/articles/730463 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730463-ascletis-pharma-discovers-new-thr-agonists HYJ-2 arises as candidate for uric acid disorders http://www.bioworld.com/articles/730451 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730451-hyj-2-arises-as-candidate-for-uric-acid-disorders 3D rendering of uric acid molecules in the bloodstream Sex differences shape gene activity across the human brain http://www.bioworld.com/articles/730447 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730447-sex-differences-shape-gene-activity-across-the-human-brain Brain and DNA Lilly’s GLP-1 Foundayo aces MACE in DILI of a phase III http://www.bioworld.com/articles/730389 Thu, 16 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730389-lillys-glp-1-foundayo-aces-mace-in-dili-of-a-phase-iii Foundayo Credit: Eli Lilly and Co. Corbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists http://www.bioworld.com/articles/730440 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730440-corbus-pharmaceuticals-synthesizes-new-cannabinoid-cb1-receptor-antagonists-or-inverse-agonists In the mix post-Ventyx, more NLRP3s to seize? Nature that delved into mechanisms that rev up the NLRP3 inflammasome.]]> http://www.bioworld.com/articles/730313 Wed, 15 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730313-in-the-mix-post-ventyx-more-nlrp3s-to-seize NLRP3 inflammasome Neurocrine Biosciences identifies new CRF2 receptor agonists http://www.bioworld.com/articles/730386 Wed, 15 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730386-neurocrine-biosciences-identifies-new-crf2-receptor-agonists Everest to acquire Singapore unit of Hasten Bio in $250M deal http://www.bioworld.com/articles/730419 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730419-everest-to-acquire-singapore-unit-of-hasten-bio-in-250m-deal Handshake behind digital globe Biologics in development outnumber small molecules for the first time http://www.bioworld.com/articles/730418 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730418-biologics-in-development-outnumber-small-molecules-for-the-first-time Drug research illustration Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal http://www.bioworld.com/articles/730297 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal Open capsule delivering pain relief to body Fit and fat: Study shows no such thing as metabolically healthy obesity http://www.bioworld.com/articles/730369 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730369-fit-and-fat-study-shows-no-such-thing-as-metabolically-healthy-obesity Woman exercising with hand weights Chengdu Diao Pharmaceutical discloses new apelin receptor agonists http://www.bioworld.com/articles/730340 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730340-chengdu-diao-pharmaceutical-discloses-new-apelin-receptor-agonists GLP-1R drug response tied to variants in target genes http://www.bioworld.com/articles/730325 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730325-glp-1r-drug-response-tied-to-variants-in-target-genes Illustration of the human body next to a DNA double helix Fit and fat: Study shows no such thing as metabolically healthy obesity http://www.bioworld.com/articles/730222 Fri, 10 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730222-fit-and-fat-study-shows-no-such-thing-as-metabolically-healthy-obesity Woman exercising with hand weights Biologics in development outnumber small molecules for the first time Pharma Annual Review 2026, published by Pharmaprojects, a firm that tracks global pharma R&D.]]> http://www.bioworld.com/articles/730343 Fri, 10 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730343-biologics-in-development-outnumber-small-molecules-for-the-first-time Drug research illustration Everest to acquire Singapore unit of Hasten Bio in $250M deal http://www.bioworld.com/articles/730212 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730212-everest-to-acquire-singapore-unit-of-hasten-bio-in-250m-deal Handshake behind digital globe Biologics in development outnumber small molecules for the first time http://www.bioworld.com/articles/730211 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730211-biologics-in-development-outnumber-small-molecules-for-the-first-time Drug research illustration Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity http://www.bioworld.com/articles/730241 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730241-ibios-ibio-600-cleared-to-enter-clinic-in-australia-for-obesity Tape measure, apple on scale Proqr Therapeutics expands early-stage pipeline http://www.bioworld.com/articles/730238 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730238-proqr-therapeutics-expands-early-stage-pipeline RNA strand Suzhou Spring-Sea Bio-Pharmaceuticals identifies new GLP-1R agonists http://www.bioworld.com/articles/730177 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730177-suzhou-spring-sea-bio-pharmaceuticals-identifies-new-glp-1r-agonists Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? http://www.bioworld.com/articles/730115 Mon, 06 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730115-vykat-caveat-neurocrines-29b-soleno-bid-low-ball Vykat XR Credit: Soleno Therapeutics Inc. Ambrosia slurps up a $100M series B for its oral obesity drug pipeline http://www.bioworld.com/articles/730076 Thu, 02 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline Pills, bottle, scale and-measuring tape Lilly’s Foundayo enters oral GLP-1 obesity market with speedy FDA nod http://www.bioworld.com/articles/729976 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729976-lillys-foundayo-enters-oral-glp-1-obesity-market-with-speedy-fda-nod Eli Lilly logo atop Lilly Biotechnology Center campus in San Diego, Calif. Credit: MichaelVi - stock.adobe.com Congruence Therapeutics discovers new MC4 receptor antagonists http://www.bioworld.com/articles/730070 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730070-congruence-therapeutics-discovers-new-mc4-receptor-antagonists Series B financing supports Ambrosia’s cardiometabolic pipeline http://www.bioworld.com/articles/730060 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730060-series-b-financing-supports-ambrosias-cardiometabolic-pipeline Blue digital dollar sign